Commencing in February 2016, Professor John Horvath AO joined the Company as its Strategic Medical Advisor. Professor Horvath assists
the Company in developing and implementing innovative clinical programmes which enhance the Company’s performance and reputation as
a global leader in the delivery of safe and quality care to patients. Professor Horvath is a member of the Global RMC.
As part of its strategy to continuously improve clinical governance, in August 2015 the Company announced a Strategic Alliance with the
International Consortium for Health Outcomes Measurement (ICHOM). ICHOM is a non-profit organisation founded to enable health care
systems worldwide to measure and report patient outcomes in a standardised way. By forming this Strategic Alliance, the Company was
the first multinational hospital group to partner with ICHOM, demonstrating its commitment to focus on discovering what matters most to
The Strategic Alliance with ICHOM represents the Company’s long-term commitment to driving value in health care in its facilities around
the world as the continuous measurement of what is delivered for patients will provide a key input into innovation and help to drive clinical
governance quality improvement.
With the Market
The Company is committed to complying with its continuous disclosure obligations under the ASX Listing Rules and Corporations Act and to
ensuring that its shareholders are kept well-informed of all major developments affecting the Company’s state of affairs.
The Company has a Continuous Disclosure Policy, which was reviewed and updated during FY2016 as a result of revisions to ASX Guidance
Note 8. This Policy creates a framework for compliance with relevant disclosure obligations and establishes the accountability of senior
executives for achieving compliance. More specifically, the Policy:
• explains the Company’s obligations under ASX Listing Rule 3.1 and the Corporations Act;
• establishes internal processes for reporting of information considered to be potentially price-sensitive and for consideration of such
information by the Company Secretary, the Disclosure Committee and (where necessary) the Board;
• establishes processes for the disclosure of price sensitive information;
• establishes internal processes for briefing of analysts, investor and media groups, responding to market speculation, leaks and rumours
and calling trading halts where appropriate to avoid trading occurring in an uninformed market; and
• delegates to the Disclosure Committee and Company Secretary the authority to release information or make disclosures to the ASX and
responsibility for decisions regarding price sensitive information, coordinating disclosures, establishing and monitoring procedures under
this Policy and making recommendations to the Board on any necessary updates to the Policy.
The Company is always mindful of the importance of communicating effectively with its shareholders including by allowing shareholders
access to information about the Company and its governance on its website.
A formal Communications Policy has been adopted by the Board in relation to the provision of information to shareholders, the media and the
The Communications Policy establishes internal protocols and authorisations for communications with media (including media inquiries and
releases at Company and facility level), disclosure of corporate and confidential information and communications with shareholders and
investors. The Policy is to be read in conjunction with the Continuous Disclosure Policy described above, which deals with the disclosure of
The Company’s investor relations programme comprises the following mechanisms, which together facilitate two-way communications with
shareholders and ensure that shareholders are kept fully informed and able to participate effectively at general meetings:
• financial reports, market reports and ASX releases are posted on the Investor Centre on the Company’s website;
• relevant documents relating to the Company’s governance arrangements are made available in the Corporate Governance section of the
• shareholders are able to send emails to, and can elect to receive email alerts from, the Company’s share registry manager facility, which is
provided by Boardroom Pty Limited;
• an investor email inquiry facility has been established to ensure timely responses by the Company Secretary (for individual shareholders)
or the Finance Director (for institutional shareholders) to all investor questions;
• correspondence from the Chairman is sent to shareholders for significant events (including via the Company’s website and email alerts);
• participation by shareholders at the AGM is actively encouraged. For example, shareholders are encouraged to submit questions to the
Company’s auditor prior to the AGM, with those questions answered at the AGM.
The Board has established a Remuneration Committee which, in accordance with the Remuneration Committee Charter, is responsible for
reviewing and making recommendations to the Board in respect of:
• executive remuneration and incentive policy;
• remuneration of the Company’s key management personnel, Company Secretary and any other senior executive reporting to the
• equity based incentive plans;
26 RAMSAY HEALTH CARE LIMITED